期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
皮下脂膜炎样T细胞淋巴瘤WHO-EORTC皮肤淋巴瘤分类的新概念 被引量:4
1
作者 孔蕴毅 孔今城 +3 位作者 沈磊 陆洪芬 许越香 施达仁 《临床皮肤科杂志》 CAS CSCD 北大核心 2008年第8期489-492,共4页
目的:研究皮下脂膜炎样T细胞淋巴瘤(SPTL)的临床病理特征、免疫表型、组织起源和预后。方法:按照2005年皮肤淋巴瘤世界卫生组织-欧洲癌症治疗研究组织(WHO-EORTC)新分类分析6例SPTL患者的临床资料,作常规组织病理检查和免疫组化标记,并... 目的:研究皮下脂膜炎样T细胞淋巴瘤(SPTL)的临床病理特征、免疫表型、组织起源和预后。方法:按照2005年皮肤淋巴瘤世界卫生组织-欧洲癌症治疗研究组织(WHO-EORTC)新分类分析6例SPTL患者的临床资料,作常规组织病理检查和免疫组化标记,并对6例患者石蜡组织和1例患者冰冻新鲜组织切片进行βF1标记。结果:6例患者中男2例,女4例,中位年龄25.5岁。临床皮损以无痛性皮下结节和(或)斑块为主,少数患者有发热、贫血和脾大。瘤细胞主要限于皮下脂肪组织内,有异形性和核分裂,并见不同程度脂肪坏死和组织细胞吞噬现象。瘤细胞表达βF1、CD3、CD8、TIA-1、GB、LCA和CD45RO,不表达CD4、CD30、CD56、CD20和CD79a。6例SPTL患者平均随访37个月内均获缓解,仅1例在确诊42个月后因并发糖尿病、高血压及心衰而死亡。结论:SPTL是一种起源于αβT淋巴细胞的罕见类型细胞毒性皮肤淋巴瘤,临床病程迁延反复,5年生存率高达80%以上。完整充分的免疫组化标记对SPTL的确诊和分型必不可少。 展开更多
关键词 T细胞淋巴瘤 脂膜炎 淋巴瘤分类 whoeortc
下载PDF
Relative frequency and survival of primary cutaneous lymphomas: a retrospective analysis of 98 patients 被引量:3
2
作者 Liu J Liu YH +5 位作者 Jin HZ Ma DL Qu T Wang T S un QN Yu X 《Chinese Medical Journal》 SCIE CAS CSCD 2014年第4期645-650,共6页
Background The World Health Organization and European Organization for Research and Treatment of Cancer (WHOEORTC) classification in 2005 promoted the comparisons of primary cutaneous lymphoma (PCL) subtypes betwe... Background The World Health Organization and European Organization for Research and Treatment of Cancer (WHOEORTC) classification in 2005 promoted the comparisons of primary cutaneous lymphoma (PCL) subtypes between different countries.The relative frequency of PCL varied according to geography.The study aimed to analyze the relative frequency and survival of PCLs in China and to compare the data with the published results from other countries.Methods We analyzed 98 patients with PCLs over a 6-year period and reclassified them according to the most recent WHO-EORTC classification (2005).Disease-specific survival rate and curves according to specific subtypes such as mycosis fungoides,lymphomatoid papulosis,and primary cutaneous peripheral T-cell lymphoma,unspecified was also calculated.Results The relative rate of PCL in China was distinct from those in Western countries.Our study showed a higher frequency of cutaneous T-and NK-cell lymphomas (CTCLs) (94%),and a lower frequency of cutaneous B-cell lymphomas (CBCLs) (6%).The 5-year survival rate of the total PCLs was 82%.There was no significant difference in the 5-year survival rate (P 〉0.05 by Log-rank test) between CTCL (80%) and CBCL (100%).Conclusions The higher percentage of CTCL in China may provide a clue to further study the etiological factors of PCLs.Racial variations in factors such as HLA determinants may play a role in the development of CTCL. 展开更多
关键词 primary cutaneous lymphomas mycosis fungoides FREQUENCY survival rate who-eortc classification
原文传递
The Clinical Pathologic Analysis of Radiotherapy for Cutaneous B-cell Lymphoma
3
作者 王晓伟 潘琼 +1 位作者 Lagrange JL 张良明 《Chinese Journal of Clinical Oncology》 CSCD 2008年第1期40-43,共4页
OBJECTIVE To report results of radiation therapy treatment of 30 B-cell lymphoma patients with an initial cutaneous presentation according to the new classification by the WHO/EORTC. METHODS Thirty patients with cutan... OBJECTIVE To report results of radiation therapy treatment of 30 B-cell lymphoma patients with an initial cutaneous presentation according to the new classification by the WHO/EORTC. METHODS Thirty patients with cutaneous B-cell lymphoma (CBCL) were treated by cutaneous irradiation based on the number and location of the lesions and the stage of their tumor. Treatment was conducted using a Satume Clinac. RESULTS A complete response (CR) from the treatment for our series was 86%. The length of complete remission ranged from 4 to 301 months. Three patients (11%) developed a partial response (PR). One patient was progressive. Disease-free survival(DFS) at 10 years was 87%. Three patiens died [One PCMZL two PCLBCL leg type (29%)]. Radiotherapy was generally well tolerated. CONCLUSION According to the WHO/EORTC classification, the survivor results were good for PCMZL and PCFCL. The PCLBCL leg type had a poor prognosis. Localized field irradiation is an effective treatment for some localized forms of primary cutaneous B-cell lymphoma, and this mode of therapy can produce prolonged remissions.The patients with wide-spread skin involvement are usually candidates for extended field irradiation and/or chemotherapy. For advanced stages of cutaneous B-cell lymphoma, where chemotherapy is the treatment of choice, a degree of palliation can be achieved using local field irradation. 展开更多
关键词 who/eortc classification cutaneous B-cell lymphoma radiotherapy.
下载PDF
放射治疗皮肤B细胞淋巴瘤30例临床分析
4
作者 王晓伟 张良明 《青岛医药卫生》 2007年第2期84-87,共4页
目的根据WHO/EORTC最新分期,报告30例原发性皮肤B细胞淋巴瘤患者的放疗效果。方法选取30例皮肤B细胞淋巴瘤患者接受皮肤放射治疗。根据病灶数量及病灶部位分别将患者分组。使用的治疗机为SATURNE CLINAC。统计软件为SPSS10.0。结果... 目的根据WHO/EORTC最新分期,报告30例原发性皮肤B细胞淋巴瘤患者的放疗效果。方法选取30例皮肤B细胞淋巴瘤患者接受皮肤放射治疗。根据病灶数量及病灶部位分别将患者分组。使用的治疗机为SATURNE CLINAC。统计软件为SPSS10.0。结果完全缓解(CR)为86%,完全缓解时间4-301个月;3例患者部分缓解(PR)为11%;1例进展。患者10年总生存率为87%。3例患者死亡(1例PCMBCL,2例PCLBCL小腿型29%)。所有患者都能耐受放疗。结论根据WHO/EORTC分期,PC—MBCL和PCFCL生存率高。PCLBCL下肢型预后较差。局部野对局部病灶有治疗效果,并能保持长期缓解。弥散病灶患者通常采用扩展野和/或化疗。对于进展期的病人,化疗是治疗选择,同时使用局部野治疗获得良好的姑息疗效。 展开更多
关键词 who/eortc分期 皮肤B细胞淋巴瘤 放射治疗
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部